HK StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

XUANZHUBIO-B

64.100

+0.5000.79%

Volume:346.43K

Turnover:21.92M

Market Cap:33.20B

PE:- -

High:64.500

Open:63.400

Low:62.600

Close:63.600

52wk High:72.000

52wk Low:23.820

Shares:517.95M

HK Float Shares:160.70M

Volume Ratio:0.77

T/O Rate:0.22%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:35.86

PE(LYR):- -

PS:949.09

Loading ...

Overview Company News Filings

Xuanzhu Biopharmaceutical (02575) Publishes Monthly Return for October 2025

Bulletin Express

HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 9% at Close to Hit Record High After NG-350A Granted FDA Fast Track Designation

BRIEF-Xuanzhu Biopharmaceutical Says NG-350A Granted Fast Track Designation By U.S. FDA

Xuanzhu Biopharmaceutical (2575) Announces U.S. FDA Fast Track Designation for NG-350A

Bulletin Express

XUANZHUBIO-B (02575): NG-350A Granted FDA Fast Track Designation

Xuanzhu Biopharmaceutical Co Ltd - Ng-350a Granted Fast Track Designation by U.S. FDA

THOMSON REUTERS

Hong Kong Stock 52-Week Highs and Lows Statistics | October 22

Shares of Chinese Drugmaker Xuanzhu Surge After Breast Cancer Trial Data

HK Stocks Update | XUANZHUBIO-B (02575) Rises by 30% Following ESMO Announcement on Phase III Clinical Data for Palbociclib in Breast Cancer

HK Movers | HK's Biotech Shares Soar. Xuanzhu Bio up 19%; TransThera up 13%

Tiger Newspress

Xuanzhu Biopharmaceutical's Bireociclib Shows Strong Efficacy in Phase 3 Breast Cancer Study

MT Newswires Live

Xuanzhu Biopharmaceutical (2575) Announces Positive Phase III Data of Bireociclib at ESMO 2025

Bulletin Express

XUANZHUBIO-B (02575) Presents Phase III Study Data of Palbociclib for HR+/HER2- Advanced Breast Cancer at 2025 ESMO

Hong Kong Stock Movement: XUANZHUBIO-B (02575) Surges Over 14%, More Than Triples Since IPO, Company Enters Commercialization Boom This Year

Xuanzhu Biopharmaceutical Soars 154% in Hong Kong Debut

MT Newswires Live

XUANZHUBIO-B (02575) Targets to Become Hong Kong's New Biopharma Benchmark with "Dual-Wheel Drive + Three Commercialization Pillars" Strategy

Stock Track | XUANZHUBIO-B Skyrockets 163.79% on Hong Kong Stock Exchange Debut, Reflecting Strong Investor Demand

Hong Kong Indexes Open Higher with Hang Seng Up 1.08%, Tech Index Gains 1.31%; Tech and Gold Stocks Rise Broadly, Chinese Brokerages Active, XUANZHUBIO-B Surges 154% on Debut

Shares of Xuanzhu Biopharmaceutical Set to Open at HK$29.46 Each in Hong Kong Debut VS Offer Price HK$11.60 Apiece

THOMSON REUTERS

Xuanzhu Biopharmaceutical Raises HK$701 Million from Hong Kong IPO Ahead of Trading Debut

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02575/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02575","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"XUANZHUBIO-B","latestPrice":64.1,"timestamp":1763021314350,"preClose":63.6,"halted":0,"volume":346426,"delay":0,"floatShares":160701996,"shares":517947790,"eps":0,"marketStatus":"Not Yet Opened","change":0.5,"latestTime":"11-13 16:08:34","open":63.4,"high":64.5,"low":62.6,"amount":21917564,"amplitude":0.029874,"askPrice":64.1,"askSize":2500,"bidPrice":63.4,"bidSize":3500,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1763083800000},"marketStatusCode":0,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":63.6,"openAndCloseTimeList":[[1762997400000,1763006400000],[1763010000000,1763020800000]],"volumeRatio":0.7680982879508569,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02575\",,,,,undefined,":{"symbol":"02575","floatShares":160701996,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7680982879508569,"shares":517947790,"dividePrice":0,"high":64.5,"amplitude":0.029874,"preClose":63.6,"low":62.6,"week52Low":23.82,"pbRate":"35.86","psRate":"949.09","week52High":72,"institutionHeld":0,"latestPrice":64.1,"committee":0.166667,"eps":0,"divideRate":0,"volume":346426,"delay":0,"ttmEps":0,"open":63.4,"prevYearClose":11.6,"prevWeekClose":64.95,"prevMonthClose":63.6,"prevQuarterClose":11.6,"fiveDayClose":69.65,"twentyDayClose":26.3,"sixtyDayClose":11.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02575\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02575\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02575\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02575\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02575","date":"2025-11-12","current":-54.21583,"percent":0.421053,"low":-59.374256,"twenty":-55.744273,"median":-53.927391,"eighty":-36.85516,"high":-22.444691,"avg":-48.090577,"sd":11.651789,"marketCap":32941479444},"quantilePoints":[{"date":"2025-10-17","current":-28.93414,"twenty":-27.261252,"median":-24.751919,"eighty":-23.367582,"marketCap":17558430081},{"date":"2025-10-24","current":-50.850969,"twenty":-50.816841,"median":-33.923646,"eighty":-26.424807,"marketCap":30869688284},{"date":"2025-10-31","current":-54.182971,"twenty":-53.663557,"median":-50.808309,"eighty":-28.95487,"marketCap":32941479444},{"date":"2025-11-07","current":-55.367666,"twenty":-55.639174,"median":-53.630543,"eighty":-30.992132,"marketCap":33640708960},{"date":"2025-11-12","current":-54.21583,"twenty":-55.744273,"median":-53.927391,"eighty":-36.85516,"marketCap":32941479444}],"updateTime":1763071726509},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02575\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1126191866","title":"Xuanzhu Biopharmaceutical (02575) Publishes Monthly Return for October 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1126191866","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126191866?lang=en_us&edition=fundamental","pubTime":"2025-11-06 16:43","pubTimestamp":1762418594,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (02575) announced its monthly return for the period ended 31 October 2025. According to the filing, the company’s total issued H shares remained at 160,701,996,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"1132711582","title":"HK Stock Movement | XUANZHUBIO-B (02575) Surges Over 9% at Close to Hit Record High After NG-350A Granted FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1132711582","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132711582?lang=en_us&edition=fundamental","pubTime":"2025-11-06 15:54","pubTimestamp":1762415678,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) surged over 9% in late trading, reaching a record high of HK$71.6. By the time of writing, the stock was up 6.41% at HK$69.7, with a turnover of HK$38.59 million. The rally...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","NG","02575"],"gpt_icon":0},{"id":"2578339937","title":"BRIEF-Xuanzhu Biopharmaceutical Says NG-350A Granted Fast Track Designation By U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2578339937","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578339937?lang=en_us&edition=fundamental","pubTime":"2025-10-28 18:37","pubTimestamp":1761647874,"startTime":"0","endTime":"0","summary":"BRIEF-Xuanzhu Biopharmaceutical Says NG-350A Granted Fast Track Designation By U.S. FDAOct 28 (Reuters) - Xuanzhu Biopharmaceutical Co Ltd 2575.HK:NG-350A GRANTED FAST TRACK DESIGNATION BY U.S. FDAFurther company coverage: 2575.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"1189413377","title":"Xuanzhu Biopharmaceutical (2575) Announces U.S. FDA Fast Track Designation for NG-350A","url":"https://stock-news.laohu8.com/highlight/detail?id=1189413377","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189413377?lang=en_us&edition=fundamental","pubTime":"2025-10-28 17:15","pubTimestamp":1761642933,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (2575), a subsidiary of Sihuan Pharmaceutical Holdings Group Ltd., announced that NG-350A—licensed from clinical-stage oncology company Akamis Bio Ltd.—has been...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"1123100355","title":"XUANZHUBIO-B (02575): NG-350A Granted FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1123100355","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123100355?lang=en_us&edition=fundamental","pubTime":"2025-10-28 16:44","pubTimestamp":1761641068,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) announced that NG-350A, a product licensed from clinical-stage oncology company Akamis Bio Ltd. (Akamis), has been granted Fast Track designation by the U.S. Food and Drug...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NG","BK4017","02575"],"gpt_icon":0},{"id":"2578938379","title":"Xuanzhu Biopharmaceutical Co Ltd - Ng-350a Granted Fast Track Designation by U.S. FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2578938379","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578938379?lang=en_us&edition=fundamental","pubTime":"2025-10-28 16:30","pubTimestamp":1761640242,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nFWN3W90C9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575"],"gpt_icon":0},{"id":"1188958602","title":"Hong Kong Stock 52-Week Highs and Lows Statistics | October 22","url":"https://stock-news.laohu8.com/highlight/detail?id=1188958602","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188958602?lang=en_us&edition=fundamental","pubTime":"2025-10-22 16:42","pubTimestamp":1761122564,"startTime":"0","endTime":"0","summary":"As of the close on October 22, 34 stocks reached their 52-week highs. Leading the pack were HAINA INTEL 01645 with a high rate of 37.57%, followed by ICONCULTURE 08500 at 35.16%, and 1957 & CO. 08495...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1137","IE00BYV24P56.USD","02575","LU1522347837.USD","LU2097828631.EUR","BK1117","LU1048588211.SGD","LU1023057109.AUD","IE00BZ08YR35.GBP","BK1100","LU2097828805.USD","LU0417516571.SGD","02637","06603","02589","IE00BVYPNQ40.USD","LU1634259557.SGD","LU0314109678.HKD","BK1152","IE00BQJZWZ67.USD","LU0417516902.SGD","LU1048596156.SGD","LU2293587155.HKD","BK1236","LU1634259391.SGD","08500","LU0348783233.USD","BK1227","09141","LU0572944931.SGD","08460","LU0640798160.USD","01703","BK1507","LU0181495838.USD","BK1210","LU0463099449.HKD","LU0828237940.HKD","IE00BZ08YS42.EUR","SG9999001093.SGD","01858","09893","IE00BGHQDM52.EUR","LU0607220059.USD","LU2039709279.SGD","LU1831875114.USD","00857","01429","BK1124","IE0031814852.USD","BK1528","IE00BZ08YT58.USD","LU2097828714.EUR","08178","06610","LU1251922891.USD","LU1303224171.USD","LU1115378108.SGD","00089","LU1102505929.USD","IE00BWDBJ730.SGD","01288","LU0469268626.HKD","BK1521","BK1208","IE00BVYPNP33.GBP","01867","BK1125","SG9999004311.SGD","LU0359202008.SGD","LU1497733631.SGD","LU0561508036.HKD","BK1162","03435","LU0594300179.USD","LU1188198961.HKD","LU0052750758.USD","00670","LU2399975544.HKD","BK1233","LU1961090484.USD","BK1589","LU1969619763.USD","BK1231","LU0405327148.USD","LU0293314216.USD","09869","01742","00314","00315","LU0650527681.SGD","01651","LU1770034418.SGD","09909","BK1226","01638","03141","LU1102505762.USD","LU1720050803.USD","BK1560","08495","BK1158","BK1530","BK1163","BK1585","LU0634319403.HKD","IE00B031HY20.USD","LU1282651048.USD","BK1561","02955","BK1240","IE00B5MMRT66.SGD","BK1237","LU2097828474.EUR","00465","BK1123","BK1229","BK1536","IE0008368742.USD","BK1555","00953","01959","02865","00917","IE00B031J352.USD","00991","02325","LU2097828557.USD","LU0359201612.USD","LU0594300419.USD","LU0605514214.HKD","LU0708995583.HKD","SG9999014674.SGD","08549","BK1111","LU0348784397.USD","BK1514","BK1148","IE00B543WZ88.USD","LU1719994722.HKD","LU0611395673.USD","BK1183","LU0326950275.SGD","LU0348827113.USD","LU1813983027.USD","08305","LU1282651121.HKD","02313","BK1200","08191","01872","08311","LU1224444064.USD","BK1247","LU2460026573.USD","BK1128","IE00BPRC5H50.USD","BK1138","LU0287142896.SGD","03143","BK1258","BK1219","IE00B29SXG58.USD","02587","BK1154","06182","LU0244354667.USD","LU2488822045.USD","LU0320764599.SGD","LU0140636845.USD","01709","LU2045819591.USD","BK1193","IE00B19Z5X02.USD","LU1497733557.USD","00412","01660","LU0348783662.USD","LU0348805143.USD","LU0405327494.USD","LU0821914370.USD","LU2125910500.SGD","02605","BK1542","LU0540923850.HKD","06687","LU1497734951.SGD","IE00BMCWC346.EUR","LU0417516738.SGD","LU1794554557.SGD","BK1616","LU0173614495.USD","LU0348825331.USD","LU0149534421.HKD","02169","01645","LU1328277881.USD","SG9999006597.SGD","LU0327786744.USD","BK1230","BK1582","LU2328871848.SGD","00422","02367","BK1207","LU0072462343.USD","BK1239","01780","LU1808992512.USD","BK1587","01115","SG9999003461.SGD","LU0348735423.USD","IE0008369823.USD","LU0211977185.USD"],"gpt_icon":1},{"id":"2577438356","title":"Shares of Chinese Drugmaker Xuanzhu Surge After Breast Cancer Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2577438356","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577438356?lang=en_us&edition=fundamental","pubTime":"2025-10-22 16:18","pubTimestamp":1761121080,"startTime":"0","endTime":"0","summary":"Shares of Xuanzhu Biopharmaceutical surged Wednesday after it gave an update on a clinical trial for a breast cancer drug, coming amid rising investor enthusiasm toward the Chinese pharma sector.The Beijing-based company's stock rose over 30% in Hong Kong, reaching its highest levels since listing earlier this month, outperforming the Hang Seng Biotech index, which was down 2%.Shares were last at HK$58.60 versus the IPO price of HK$11.60, implying a market capitalization of about US$3 billion, according to LSEG data.The Chinese drugmaker, which was spun off from Hong Kong-listed Sihuan Pharmaceutical, said in a filing Wednesday that it had presented interim analysis results of a Phase III clinical study of its Bireociclib treatment for advanced breast cancer.Xuanzhu said the data indicated that the experimental drug can reduce the risk of disease progression or death by 47%, compared with standard endocrine therapy combined with placebo.China's biotech companies have made significant a","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6dbeba4b9216bf67b1faa04c809b62c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Shares of Chinese Drugmaker Xuanzhu Surge After Breast Cancer Trial Data","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2028103732.USD","LU1989772923.USD","LU0912757837.SGD","LU1244550221.USD","BK4127","LU2111349929.HKD","LU0795875169.SGD","BK4581","LU1720051017.SGD","LU1244550494.USD","LU1244550577.SGD","LU1074936037.SGD","LU1363072403.SGD","LU0882574139.USD","BK4585","LU1989772840.SGD","LU0006306889.USD","LU2271345857.HKD","LU1732799900.SGD","LU0098860793.USD","BK4516","LU0267386448.USD","BK4534","LU1162221912.USD","LU0158827781.USD","BK4504","LU0320765646.SGD","BK4588","LU0795875086.SGD","LU1548497426.USD","LU1732800096.USD","LU0234570918.USD","LU0106831901.USD","LU1720051108.HKD","LU0225283273.USD","LU2357305700.SGD","LU1668664300.SGD","LU2347655156.SGD","LU2023251221.USD","LU0314104364.USD","LU2089283258.USD","LU0106261372.USD","IE00BKVL7J92.USD","02575","LU2089284900.SGD","IE00BZ1G4Q59.USD","LU2133065610.SGD","LU0557290698.USD","LU0158827948.USD","LU0971096721.USD"],"gpt_icon":1},{"id":"1100345101","title":"HK Stocks Update | XUANZHUBIO-B (02575) Rises by 30% Following ESMO Announcement on Phase III Clinical Data for Palbociclib in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1100345101","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100345101?lang=en_us&edition=fundamental","pubTime":"2025-10-22 14:46","pubTimestamp":1761115585,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) continued to gain momentum in the afternoon trading session, peaking at HK$59.85, representing a staggering increase of over 415% from its IPO price of HK$11.6. As of the latest...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4134","02575","III"],"gpt_icon":1},{"id":"1130889859","title":"HK Movers | HK's Biotech Shares Soar. Xuanzhu Bio up 19%; TransThera up 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130889859","media":"Tiger Newspress","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130889859?lang=en_us&edition=fundamental","pubTime":"2025-10-22 10:09","pubTimestamp":1761098996,"startTime":"0","endTime":"0","summary":"Hong Kong’s biotech stocks rose on Wednesday.Xuanzhu Bio rose 19%; TransThera rose 13%; Boan Biotech rose 2%; CANbridge rose 1%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"069d3331287d7c7ffedd7cde87c41b57","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617","02575","06955"],"gpt_icon":0},{"id":"2577387575","title":"Xuanzhu Biopharmaceutical's Bireociclib Shows Strong Efficacy in Phase 3 Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2577387575","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577387575?lang=en_us&edition=fundamental","pubTime":"2025-10-22 09:39","pubTimestamp":1761097175,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical  showed positive interim phase 3 data for its CDK2/4/6 inhibitor Bireociclib, used in combination with letrozole or anastrozole for the first-line treatment of HR+/HER2- advanced breast cancer, according to a Wednesday Hong Kong bourse filing.The results showed that the Bireociclib regimen reduced the risk of disease progression or death by 47% compared with endocrine therapy plus placebo.The study, known as BRIGHT-3, enrolled 397 patients across 58 centers in China.Median progression-free survival in the Bireociclib group had not yet been reached after a median follow-up of 20.7 months, compared with 18.4 to 19.6 months for the control group, the filing said.Xuanzhu reported that the therapy demonstrated a 63.5% objective response rate, compared with 42.5% in the control arm, with most adverse events being reported as manageable and of low grade.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02575"],"gpt_icon":1},{"id":"1196723046","title":"Xuanzhu Biopharmaceutical (2575) Announces Positive Phase III Data of Bireociclib at ESMO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=1196723046","media":"Bulletin Express","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196723046?lang=en_us&edition=fundamental","pubTime":"2025-10-22 06:41","pubTimestamp":1761086473,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (2575) recently presented interim Phase III clinical findings (BRIGHT-3 study) on Bireociclib in combination with letrozole or anastrozole for first-line treatment...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":1},{"id":"1138390285","title":"XUANZHUBIO-B (02575) Presents Phase III Study Data of Palbociclib for HR+/HER2- Advanced Breast Cancer at 2025 ESMO","url":"https://stock-news.laohu8.com/highlight/detail?id=1138390285","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138390285?lang=en_us&edition=fundamental","pubTime":"2025-10-22 06:30","pubTimestamp":1761085820,"startTime":"0","endTime":"0","summary":"XUANZHUBIO-B (02575) has announced that it presented data on the effectiveness of palbociclib combined with letrozole or anastrozole for first-line treatment of HR+/HER2- advanced breast cancer...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","BK4225","III","HR","BK4134","02575"],"gpt_icon":1},{"id":"1157884164","title":"Hong Kong Stock Movement: XUANZHUBIO-B (02575) Surges Over 14%, More Than Triples Since IPO, Company Enters Commercialization Boom This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1157884164","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157884164?lang=en_us&edition=fundamental","pubTime":"2025-10-21 13:46","pubTimestamp":1761025573,"startTime":"0","endTime":"0","summary":"According to reports, XUANZHUBIO-B (02575) experienced a significant increase of over 14% in the afternoon session, reaching a high of HKD 38.8, over 234% above its IPO price of HKD 11.6. As of the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":1},{"id":"2575220960","title":"Xuanzhu Biopharmaceutical Soars 154% in Hong Kong Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2575220960","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575220960?lang=en_us&edition=fundamental","pubTime":"2025-10-15 09:52","pubTimestamp":1760493167,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical's (HKG:2575) shares opened 154% above the IPO price when it started trading in Hong Kong on Wednesday morning.The biopharmaceutical firm opened at HK$29.46 per share, compared with the IPO price of HK$11.60.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"23d0a55dc84f4e13e9ecdb8968b3ef23","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02575"],"gpt_icon":0},{"id":"1156896994","title":"XUANZHUBIO-B (02575) Targets to Become Hong Kong's New Biopharma Benchmark with \"Dual-Wheel Drive + Three Commercialization Pillars\" Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=1156896994","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156896994?lang=en_us&edition=fundamental","pubTime":"2025-10-15 09:51","pubTimestamp":1760493098,"startTime":"0","endTime":"0","summary":"Following the Federal Reserve's announcement of its first rate cut in September this year, the trend of global capital flowing toward emerging markets has become increasingly evident, potentially...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":1},{"id":"1193882858","title":"Stock Track | XUANZHUBIO-B Skyrockets 163.79% on Hong Kong Stock Exchange Debut, Reflecting Strong Investor Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1193882858","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193882858?lang=en_us&edition=fundamental","pubTime":"2025-10-15 09:32","pubTimestamp":1760491969,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical Co., Ltd. (XUANZHUBIO-B, stock code: 02575) made a spectacular debut on the Hong Kong Stock Exchange, with its shares soaring 163.79% in early trading on Wednesday. This...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"23d0a55dc84f4e13e9ecdb8968b3ef23","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["02575"],"gpt_icon":1},{"id":"1159408749","title":"Hong Kong Indexes Open Higher with Hang Seng Up 1.08%, Tech Index Gains 1.31%; Tech and Gold Stocks Rise Broadly, Chinese Brokerages Active, XUANZHUBIO-B Surges 154% on Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1159408749","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159408749?lang=en_us&edition=fundamental","pubTime":"2025-10-15 09:31","pubTimestamp":1760491883,"startTime":"0","endTime":"0","summary":"US stocks showed mixed performance on Tuesday, with markets initially pressured by trade war concerns causing sharp declines in early trading. However, after the Federal Reserve Chairman indicated...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"e1c2840ae2837c4c8311f5421dadad50","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCHmain","159562","MHImain","BK4614","YANG","513600","HSImain","HSI","02833","HHImain","02575"],"gpt_icon":1},{"id":"2575022734","title":"Shares of Xuanzhu Biopharmaceutical  Set to Open at HK$29.46 Each in Hong Kong Debut VS Offer Price HK$11.60 Apiece","url":"https://stock-news.laohu8.com/highlight/detail?id=2575022734","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575022734?lang=en_us&edition=fundamental","pubTime":"2025-10-15 09:21","pubTimestamp":1760491274,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"23d0a55dc84f4e13e9ecdb8968b3ef23","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nL3N3VW01X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02575"],"gpt_icon":0},{"id":"2575223550","title":"Xuanzhu Biopharmaceutical Raises HK$701 Million from Hong Kong IPO Ahead of Trading Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2575223550","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575223550?lang=en_us&edition=fundamental","pubTime":"2025-10-15 06:06","pubTimestamp":1760479592,"startTime":"0","endTime":"0","summary":"Xuanzhu Biopharmaceutical (HKG:2575) raised HK$701.0 million in net proceeds from its initial public offering in Hong Kong.The final offer price was set at HK$11.60 per share, according to an after-ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"23d0a55dc84f4e13e9ecdb8968b3ef23","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02575"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}]}}